

## Questions & Answers on the Technical Review of the Gene Technology Regulations 2001

The gene technology legislation is a scientific risk based scheme. The Regulator has [proposed amendments](#) to the Regulations to ensure the legislation keeps pace with technological change, and the level of regulation is appropriate given the potential risks. The proposed amendments address risks to human health and safety and the environment for the purposes of the gene technology legislation. All states and territories in October 2018 reaffirmed their support for science-based regulation to protect human health and safety and the environment under the [National Gene Technology Scheme](#). This includes the continuation of the intergovernmental agreement for gene technology and approving all recommendations for the recent review of the scheme.

### **Will the proposed amendments strengthen the regulation of genome editing techniques?**

Yes. There is currently legal uncertainty about the regulation of new technologies, including genome editing techniques, and these amendments will explicitly capture most genome editing techniques as requiring regulation under the legislation. One technique, known as SDN-1, is proposed to be excluded because SDN-1 organisms present no different risk than organisms carrying naturally occurring genetic changes.

### **Are genome editing techniques, including CRISPR, potentially unsafe and therefore need to be regulated?**

Most genome editing techniques will be explicitly regulated. The technique known as SDN-1 is proposed to be excluded because, based on the scientific evidence, SDN-1 organisms present no different risk than organisms carrying naturally occurring genetic changes. Organisms modified using SDN-1 cannot be distinguished from conventionally bred animals or plants, and there is no evidence that they pose safety risks that warrant regulation.

### **Do the proposed measures mean that Australia is going to deregulate genetically modified animals?**

No. Under the amendments, animals modified using all older gene technology techniques and most new genome editing techniques including CRISPR would continue to be regulated as genetically modified organisms. In contrast, some countries, such as USA, Brazil and Argentina, have implemented a broad range of regulatory exclusions for genome edited organisms.

### **Would genetically modified food safety assessment and labelling change?**

No. Amendments to the Gene Technology Regulations would not impact current requirements for food, which are set separately through the Australia New Zealand Food Standards Code.

### **Are the proposed amendments consistent with the European Union court decision that indicates genome edited organisms might pose similar risks to GMOs and should therefore undergo safety assessment?**

Yes they are. The proposed amendments will seek to explicitly regulate most gene editing techniques, including the need to undergo a safety assessment. The European Union court decision was legally based and not a scientific safety decision. The court interpreted the current legal instruments of the European Union, including the European parliament's intentions at the time of developing the laws and definitions within it, and came to a view on that basis. In contrast, the gene technology legislation is a scientific risk based scheme.

### **Would there be trade impacts for agricultural exports?**

Agricultural industry groups, including exporters, strongly supported the amendments in relation to SDN-1 being excluded from regulation. USA, Brazil, Argentina and Chile have made similar exclusions and Japan is proposing to do the same. As with trade generally, there are market risks to non-alignment in regulatory approaches, however these trade risks are not unmanageable and are quite common and familiar to the industry. A range of non-regulatory mechanisms can support trade between jurisdictions with differing regulatory requirements.

**The Office of the Gene Technology Regulator**

**Tel: 1800 181 030      E-mail: [ogtr@health.gov.au](mailto:ogtr@health.gov.au)**

**[OGTR Website](#)**